CURRICULUM VITAE

HOWARD LEN LIPPTON

CONTACT:

Howard Lippton, MD MPH MLIS

*** ****** *****

Shreveport, Louisiana 71106

Telephone: 318-***-****

e-mail: ad0sk1@r.postjobfree.com

CITIZENSHIP:

United States

LANGUAGE:

English (fluent)

EDUCATION:

Undergraduate:

08/1974 – 06/1978 Tulane – University, New Orleans, LA (Biology--B.S.) Graduate:

01/2024 – 06/2026 University of South Florida, Tampa, FL (Health Informatics---MS) 08/2022 – 06/2025 University of Florida, Gainesville, FL (Microbiology and Cell Science—MS) 08/2018 – 06/2022 University of Alabama, Tuscaloosa, AL (Library & Information Science--MLIS) 06/2006 – 06/2016 Johns Hopkins University, Baltimore, MD (Public Health--MPH) 07/1982 – 06/1984 Tulane University, School of Medicine, New Orleans, LA (Medicine--MD) 07/1981 – 06/1982 University of Florida, College of Medicine, Gainesville, FL 08/1979 – 07/1980 University of Florida, College of Medicine, Gainesville, FL TRAINING:

1988 – 1989 NIH Postdoctoral Fellow Department of Physiology, Louisiana State University School of Medicine

1987 – 1989 Fellow, Pulmonary/Critical Care Medicine Louisiana State University School of Medicine

1984 – 1987 Internship/Residency in Internal Medicine Tulane Affiliated Hospitals

2

Howard Lippton

FACULTY POSITIONS:

1999 – 2000 Professor

Louisiana Tech University, Department of Biomedical Engineering 1994 – 1998 Associate Professor

Louisiana State University, School of Medicine, Department of Pharmacology 1994 – 1995 Associate Professor

Louisiana State University, School of Medicine, Department of Internal Medicine, Section of Pulmonary/Critical Care

1992 – 1996 Assistant Professor

Tulane Medical School, Department of Surgery

1990 – 1994 Assistant Professor, Adjunct

Louisiana State University, School of Medicine, Department of Pharmacology 1990 – 1994 Assistant Professor

Louisiana State University, School of Medicine, Department of Internal Medicine, Section of Pulmonary/Critical Care

1989 – 1990 Instructor

Louisiana State University, School of Medicine, Department of Internal Medicine, Section of Pulmonary/ Critical Care

1988 – 1992 Clinical Instructor

Tulane Medical School, Department of Surgery

1982 – 1986 Instructor

Tulane Medical School, Department of Pharmacology

ARTICIAL INTELEGENCE EXPERIENCE

2021 – 2023 Co-developed an “AI brain” as software for database search and analytic construction to reduce symptoms and onset of cyberchondria in the underserved population with chronic diseases including asthma, hypertension, and diabetes; minimized search hallucinations; Preparation of SBIR grant on clinical application CARDIOVASCULAR PHARMACOLOGY EXPERIENCE

1979 – 2023 Extensive Basic Science, Clinical, and Corporate; Experimental Design, Conduct Experiments, Statistical Analyses of Experimental Results, Oral Presentation of Results, Grant Cycle Events Including Preparation, Submission, Oversight and Monitor Grant Awards, Attained Academic Rank of Professor, Executive and Administrative Leadership Roles; Ownership/Operational Management of Biotech Start-ups, Contract Sales EDITORIAL BOARD (MEDICAL JOURNALS)

1983-1996 Journal of Applied Physiology, Peptides, American Journal of Physiology, and Prostaglandins

3

Howard Lippton

FUNDRAISING AND CORPORATE SPONSORSHIP CULTIVATION EXPERIENCE: 2015-2019 Lead for community corporate and individual support on a multiyear basis for Lippton Health Center, a non-profit medical clinic for ex-inmates with chronic diseases including Hepatitis C, Hepatitis B, and HIV

HEALTH LITERACY AND PROMOTION EXPERIENCE:

1990 – 1995 Volunteer as Assistant Director City of New Orleans Developed health literacy promotion program for outreach to address diabetes management in underserved populations in Uptown and Mid City neighborhoods of New Orleans; coordinate physician care; build core competencies in educating, testing, diagnosing, and treating vulnerable individuals on diabetes management. 1995 – 1998 Volunteer as Assistant Director City of New Orleans Created and deployed educational program with the American Heart Association for recognition, clinical treatment, and medicine compliance for hypertension in underserved populations including African American and Hispanic populations in New Orleans. 2000 – 2002 Medical Director of Student Infirmary at Grambling State University

– An Historically Black University and College (HBUC) Developed and evaluated content for campus-wide program to educate college students on sexually transmitted infections (STI). Instituted STI program using seminars and multimedia presentations; Employed newly-created monitoring techniques including class course questionnaires as metrics to determine the efficacy of the program (empiric partner treatment) to increase treatment efficacy for on-campus students with STI. 2006 – 2017 Medical Director of Jonah Healthcare Inc Developed proprietary questionnaires using Likert scale to build clinical competencies among corporate employees and and measure the level of knowledge decay of underserved patients. Performed a series of seminars on diabetes prevention/food choices in Brookshire grocery stores located in neighborhoods with vulnerable and underserved populations. Novel approach to use health promotion to assess the “health” of a community.

2009 – 2012 Volunteer as Public Health Coordinator and Team Leader Assessed, created, implemented, and evaluated regional plan to control syphilis in vulnerable and underserved populations. Developed multimedia modules to address health literacy and educate local clinicians on scope, treatment access, and treatment failures of syphilis. Communicated and coordinated entire program with CDC and State of Louisiana Public Health Department.

2013 – 2015 Volunteer as City Director

Created city-wide education and health literacy campaign for weight reduction for the uninsured and underserved populations in Shreveport, LA. Served as communication hub/focal point for clinical use of newly approved drugs including glucagon-like peptide- 1 (GLP-1) agonists for weight reduction. Planning for agenda, protocol, and content material for health promotion and weight reduction material for local medical clinics. 4

Howard Lippton

2015 – 2018 Volunteer as Medical Director/ Lippton Health Center Created and operated a non-profit corporation to provide free medical care to individuals released from prison. Due to the high frequency of illiteracy and learning disabilities among individuals in this population, health promotion and health literacy to address Hepatitis C was customized and individualized to ensure knowledge dissemination. 2018 – present Lead Developer at Medical Research Direct LLC Using Qualtrics to create online assessment tools to assess knowledge decay following health promotion and public health education campaigns in underserved populations. Novel AI to improve health promotion strategies and deploy search and metrics for cyberchondria.

INFECTION CONTROL AND PREVENTION EXPERIENCE

2015 – 2021 Lippton Health Center

Infection prevention for immunocompromised patients in non-profit clinic Directed and administered infection control and prevention for the entire facility ensuring A,B,Cs: Asepsis, Body Hygiene, and Caring Attitude; developed and deployed all policies to detect, prevent, and control the spread of infection in the healthcare facility for patient and staff safety including contact precautions, droplet precautions, airborne precautions, and eye protection; Enforced hand hygiene, respiratory hygiene, sharps safety, safe injection practices, and sterilization and disinfection of patient-care items and devices. These procedures necessitated full compliance for providing free medical care and lab testing for ex-inmates with active Hepatitis B, Hepatitis C, and HIV along with other chronic diseases. Effective infection prevention and control permitted the clinic to achieve quality health care delivery LIBRARY EXPERIENCE:

1987—1994 Librarian Evenings; LSU/New Orleans Medical School Library; Reshelve books and materials; organize current medical journals; assist medical students/faculty in search for research articles and develop reviews of patron-chosen topics: collections; circulation desk; performed collections audit and inventory control; technical services; began program for long-term digital transformation of teaching and reference material for medical personnel.

LONG-TERM CARE EXPERIENCE

1989-1994 Faculty Medical Practice—exclusively long-term acute care at three hospitals

1994-1995 Solo Medical Practice—exclusively long-term acute care at three hospitals

1995-2001 Owner/Medical Director respiratory care company with fifty-six respiratory care therapists providing care for ventilator patients at three nursing homes

5

Howard Lippton

OBESITY, LIPIDS, AND DIABETES EXPERIENCE

2007 – 2017 Created and Deployed Diabetes and Weight Control Programs Focused on SGLT2 inhibitors and GLP-1 agonists; Comprehensive approach using subscription patient model to cash-based healthcare to offer unlimited access to control constellation of sequelae to obesity; Created “Freight Management” program utilizing GLP-1 agonists including Trulicity, Bydureon, Victoza, and Saxenda; lipid management. SALES EXPERIENCE:

2009 – 2014 Owner/President/Director of Operations of Barrakooda Bites LLC Single store-front location in Shreveport, LA next door to Total Care Medical Clinic; Retail sales of coffee cakes, frozen desserts, custom cakes all from bakeries in Boston, MA and New Orleans, LA; inventory, sales, marketing, and staffing SUPERVISORY AND MANAGEMENT EXPERIENCE:

1989 – 1993 Director Pulmonary Function Lab Charity Hospital/New Orleans Oversaw time management, quality control, budget, training, conflict resolution; supervision of one-hundred fifty employees.

1989 – 1994 Supervisor

Direct training in effective and productive research, publication of research, and grant writing; supervised sixteen post-doctoral fellows from foreign countries. 1995 – 2002 President of Lung Care Inc.

Negotiated business contracts; responsible for quality certification in providing respiratory care 24 hrs/day at seven days a week to ventilator patients; directed a marketing team; performed leadership role; managed organizational activities; responsible for oversight of perpetual training; supervised seventy-five employees including ten physicians.

1996 – 1999 President of HLL Labs

Biotech-startup; lead for drug development; developed plan and executed plan for capital investment; budgetary and financial oversight; time-management among employees and project development; delegation and oversight of daily business operations; designed and performed experiments in vivo and in vitro; supervised three employees. 2000 – 2002 Supervisor and Manager of Howard Lippton MD LLC Undertook all financial and budgetary responsibilities of medical clinic; oversight of twenty-five employees including clinicians and administrative staff; negotiated with insurance companies and Medicare Part B; supervised twenty-five employees. 2002 – 2006 President of Pneumosite LLC

Biotech start-up; lead for development of biomedical devices; managed day-to-day business activities; supervised two employees.

2006 – 2017 President of Jonah Healthcare Inc.

Negotiated with Medicare Part D over patient medications, operated primary care medical clinic; training of employees; negotiated consultant contracts; developed novel subscription care model; supervised thirty-five employees. 2018 – present President Medical Research Direct LLC Currently developing proprietary information systems for individual patient to determine degree of knowledge decay in real-time for outpatient medical care. 6

Howard Lippton

TEACHING EXPERIENCE:

1978 – 1998 Tulane Medical School

Instruction for medical students of hands-on animal laboratory techniques for demonstration, investigation, and identification of unknown pharmacological agents 1984 – 1994 LSU and Tulane Medical Schools

Development of course instructional material for core medical student curriculum in multiple courses including Pharmacology, Internal Medicine, and Pulmonary Medicine

1987 – 1990 Tulane Medical School

Instruction guides for senior medical students; Dean-sponsored special seminars for year-round weekly patient-oriented discussions with course material and current literature; Developed and created all material and content de novo. 1989 – 1994 LSU Medical School

Daily teaching hospital patient rounds with house officers including fellows; interns, residents, and students.

1989 – 1994 Tulane Medical School

Developed content for 8-week course for graduate students on writing and publishing research. Instituted course continuously every 8 weeks with instructional meetings 1991 – 1994 LSU Medical School

Member Curriculum Committee; tasked to enhance delivery of course content to medical students.

WORK EXPERIENCE:

06/1978 – 07/1979 Research Scientist

Tulane Medical School, Department of Pharmacology, New Orleans, Louisiana

(60 hrs/wk)

07/1980 – 06/1981 Research Scientist

Tulane Medical School, Department of Pharmacology, New Orleans, Louisiana (On leave of absence from University of Florida)

(60 hrs/wk)

07/1984 – 06/1987 Intership/Residency Training:

Tulane Medical School

(90 hrs/wk)

07/1987 – 06/1994 Librarian

LSU Medical School

(20 hrs/week)

07/1987 – 06/1989 Fellowship Training

LSU Medical School

(70 hrs/wk)

07/1989 – 06/1993 Director

Pulmonary Function Laboratory, Charity Hospital of New Orleans

(20 hrs/wk) salary included in faculty salary

7

Howard Lippton

07/1989 – 06/1990 Faculty Position/Instructor

LSU Medical School

(70 hrs/wk)

07/1990 – 06/1994 Faculty Position/Assistant Professor LSU Medical School

(70 hrs/wk)

07/1994 – 08/1994 Faculty Position/Associate Professor LSU Medical School

(70 hrs/wk)

08/1994 – 05/1995 Private Solo Practice

Hospitalist for long-term ventilator care

(90 hrs/wk)

06/1995 – 12/2002 Owned/Operated Lung Care, Inc.

Clinical respiratory care company for nursing homes in the New Orleans area. Leadership/Medical Director

(50 hrs/wk)

01/1996 – 12/1999 President – HL Labs, Inc.

Biomedical research on peptidergic and endothelial control mechanisms of the pulmonary circulation; pre-clinical development of antibody for endothelin receptor blockade

(40 hrs/wk)

01/2000 – 07/2002 Owned/Operated Howard Lippton MD LLC Primary care clinics Louisiana

(90 hrs/wk)

08/2002 – 09/2006 Owned/Operated Pneumosite LLC

Biomedical drug and device development

(60 hrs/wk)

10/2006 – 12/2017 Owned/Operated Jonah Healthcare d/b/a Total Care Medical Clinic Cash primary care medical practice; Principal Investigator Clinical Trials

(80 hrs/wk)

05/2015 – 12/2021 Founder/President--Lippton Health Center LLC Non-profit corporation providing free medical care to ex-inmates on parole

(10 hrs/wk)

05/2009 – present Own/Operate Medical Research Direct LLC Develop modules to assess knowledge decay in patients in real-time clinical practice; study role of cyberchondria to influence health promotion, healthcare delivery, and individual health

(currently 40 hrs/wk)

SOCIETY MEMBERSHIP:

Alpha Omega Alpha Medical Honor Society

American Society of Clinical Investigation

Shreveport Medical Society

Medical Library Association

American Library Association

8

Howard Lippton

GRANT SUPPORT:

Clinical Research:

1990-1994 Principal Investigator

Sepsis, GMCSF, Pneumonia, Hypertension, IV contrast agent studies Basic Science Research

1989-1994 Principal Investigator

NIH RO1 grant “Synaptic Location Determines Type of Modulation of Peripheral Adrenoceptors” 1994-1998 Principal Investigator

NIH RO1 grant “Endothelial Regulation of the Pulmonary Circulation” 1985-1989 Co-Investigator

NIH RO1 grant “Neural Control of the Pulmonary Vascular Bed” 1989-1994 Co-Investigator

NIH RO1 grant “Tone-Dependent Mechanisms in the Pulmonary Circulation” 1981-1990 Principal Investigator

Grants from the National American Heart Association, American College of Chest Physicians, Louisiana American Heart Association, Louisiana Education Trust Fund (LEQSF) 1991-1996 Established Investigator Grant

American Heart Association “Endothelin---Novel Receptor Transduced by Voltage-regulated Potassium Channels.”

AWARDS:

Alpha Omega Alpha Medical School Honor Society, Stars and Bars Chapter Tulane Medical School

Medical Student Clerkship in Cerebrovascular Disease American Heart Association

1980- 1981.

Medical Student Fellowship

Louisiana Heart Association

Summers of 1981, 1982, 1983.

Medical Student Research

Fellowship University of

Florida

1982-1983.

Short Term Research Training Fellowship

Tulane University

1983.

Medical Student Research Fellowship in Pharmacology Pharmaceutical Manufacturer’s Association Foundation 1983-1984.

9

Howard Lippton

Dr. Sam Hobson Prize in Physical Diagnosis

Tulane Medical School

1984.

John T. Halsey Award for Outstanding Achievement in Pharmacology Tulane Medical School

1984.

Jorgen U. Schlegel Award for Excellence in Research Tulane Medical School

1988.

Award for Chest Disease Research

Southern Medical Association

1988.

Fellowship Grant “Peptidergic Regulation of the Peripheral Circulation” NIH 1988-89.

Physician Scientist Award

American College of Chest Physicians

1990-1992.

Established Investigatorship

American Heart Association

1992-1997.

Elected: American Society for Clinical Investigation 1995.

INVITED PRESENTATIONS:

“Thromboxane-dependent Vasoconstriction in the Lung,” Fourth International Symposium on Prostaglandins, Dusseldorf, Germany, October 5-7, 1988.

“Neuropeptide Regulation of the Pulmonary Vascular Bed,” Katholieke Universitet Leuven, Belgium, October 1988.

“Lipid Mediators that Control Lung Function” at Louis Pasteur Institute, July 6, 1987.

“Endothelin – A polypeptide with Novel Hemodynamic Activity” 5th European Shock Congress in Neum, Yugoslovia, October 1988.

“Effects of Endothelin in the Pulmonary and Systemic Vascular Beds in vivo” symposium on Endothelin, American Society of Pharmacology and Experimental Therapeutics, FASEB, New Orleans, March 21, 1989.

“Endothelial Regulation of the Pulmonary Vascular Bed: In Vivo Comparisons of the Infant and Adult:” at symposium on “Control of the Pulmonary Circulation,” American College of Cardiology, New Orleans, LA, March 20, 1990.

“Cardiovascular Effects of Endothelin,” Second International Conference on Endothelin; Tsukuba, Japan, December 9-12, 1990.

“Neural Control of the Pulmonary Circulation,” International Congress for Pathophysiology, Moscow, U.S.S.R., May 28 – June 1, 1991.

“Recent Advances in Pulmonary Medicine,” American College of Chest Physicians,,” December 13-14, 1991.

10

Howard Lippton

“Endothelin Family in Health and Disease,” Research Institution of San Miguel de Tucuman, Argentina, Jan 1991.

“Endogenous peptides, KATP channels, and coronary vasodilation,” 4th World Congress on Heart Failure

– Mechanism and Management; Jerusalem, Israel, May 1996.

“Regulation of Endothelial Function in the Lung,” Turkish Pharmacy Society Istanbul, Turkey, May 2000. PUBLICATIONS:

1. Lippton, H.L., Paustian, P.W., Mellion, B.T., Nelson, P.K., Feigen, L.P., Chapnick, B.M., Hyman, A.L., and Kadowitz, P.J. Cardiovascular actions of prostacyclin (PGI2) in the cat. Arch. Int. Pharmacodyn. Ther. 241(1):121-***-****.

2. Lippton, H.L., Chapnick, B.M., Hyman, A.L., and Kadowitz, P.J. Inhibition of vasoconstrictor responses by prostacyclin (PGI2) in the feline mesenteric vascular bed. Arch. Int. Pharmacodyn. Ther. 241(2):214-223, 1979.

3. Lippton, H.L., Cassin, S. and Kadowitz, P.J. Comparative effects of PGD2 and PGE2 on vasoconstrictor responses in the feline intestinal vascular bed. Prostaglandins and Medicine 5:297-305, 1980.

4. Hyman, A.L., Lippton, H.L., Spannhake, E.W., Chapnick, B.M., Feigen, L.P., and Kadowitz, P.J. Nature of Adrenergic Receptors in the Pulmonary Vascular Bed (PVB). Circulation, 64: supp IV, October 1979, II-107 (413).

5. Glass, F.L., Lippton, H.L., and Kadowitz, P.J. Effects of in vitro and in vivo administration of synthetic glucocortocoids on arachidonic acid. Clinical Research 28: 1 February 1980. 6. Lippton, H.L., Chapnick, B.M., and Kadowitz, P.J. (intro. By Hyman, A.). Effects of E Series prostaglandins on vasoconstrictor responses in the feline hindquarters vascular bed. Clinical Research, 28: February 1, 1980.

7. Lippton, H.L., Paustian, P.W., Sporl, L., and Kadowitz, P.J. Comparitive effects of PGD2 and PGE2 in the regional circulation of the cat. Protaglandins and Medicine 5:365-373, 1980. 8. Lippton, H.L., Chapnick, B.M., Hyman, A.L., and Kadowitz, P.J. Inhibition of vasoconstrictor responses by 6-keto-PGE1 in the feline mesenteric vascular bed. Prostaglandins 19:299-310, 1980. 9. Glass, F., Lippton, H.L., and Kadowitz, P.J. Differential effects of local anesthetics and propranolol on arachidonic acid and adenosine 5’-diphosphate-induced aggregation in rabbit platelets. Prostaglandins and Medicine 5:85-92, 1980.

10. Gottlieb, A.L., Lippton, H.L., Parey, S.E., Paustian, P.W., and Kadowitz, P.J. Blockade of vasoconstrictor responses by prostacyclin (PGI2), PGE2, and PGE1 in the rabbit hindquarters vascular bed. Prostaglandins and Medicine 4:1-11, 1980.

11. Lippton, H.L., Chapnick, B.M., Hyman, A.L., and Kadowitz, P.J. Influence of prostacyclin on sympathetic neurotransmission in the feline intestinal vascular bed. Adv Prostaglandin Thromboxane Res. 8:1249-53, 1980.

12. Lippton, H.L., Chapnick, B.M., and Kadowitz, P.J. Influence of prostaglandins on vasoconstrictor responses in the hindquarters vascular bed of the cat. Prostaglandins and Medicine 6:183-202, 1981 13. Pontecorvo, E.G., Myers, C.B., Lippton, H.L., and Kadowitz, P.J. Inhibition of platelet aggregation by 6-keto-PGE1: lack of an effect on cyclic GMP levels. Prostaglandin and Medicine 6:473-483, 1981. 11

Howard Lippton

14. Lippton, H.L., Myer, R.L., Parey, S.E., Hyman, A.L., and Kadowitz, P.J. Analysis of responses to dopamine in the mesenteric vascular bed of the cat. Arch. Pharmacol. 251:136-149, 1981. 15. Lippton, H.L., Chapnick, B.M., Hyman, A.L., Glass, F.L., and Kadowitz, P.J. The influence of indomethacin on vasodilator responses to bradykinin and nitroglycerin in the cat. Peptides 2:165-169 16. Ignarro, L.J., Lippton, H.L., Edwards, J.C., Baricos, W.H., Hyman, A.L., Kadowitz, P.J., and Gruetter, C.A. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J.Pharmacol. Exp. Ther. 218:739-749, 1981.

17. Hyman, A.L., Mathe, A.A., Lippton, H.L., and Kadowitz, P.J. Prostaglandins and the lung. In: Medical Clinics of North America, Vol. 65. pp. 789-808, 1981. 18. Kadowitz, P.J., Lippton, H.L., McNamara, D.B., Spannhake, E.W., and Hyman, A.L. Prostaglandins and the pulmonary circulation. In: Prostaglandins and Thromboxane Research, Vol. 10. J. Oates (ed.), 1981

19. Glass, F., Lippton, H.L., and Kadowitz, P.J. Effects of methyprednisolone and hydrocortisone on aggregation of rabbit platelets induced by arachidonic acid and other aggregating substances. Thromobosis and Haemostasis 46:676-679, 1981.

20. Lippton, H.L. and Kadowitz, P.J. Inhibition of vasoconstrictor and vasodilator responses by PGE1 in the intestinal vascular bed of the cat. Prostaglandins and Medicine 7:537-552, 1981. 21. Nandiwada, P.A., Kadowitz, P.J., Lippton, H.L., Hyman, A.L., and Ignarro, L.J. Pulmonary responses to nisoldipine. Clinical Research, 29: 1 February 1981. 22. Nandiwada, P.A., Kadowitz, P.J., Lippton, H.L., and Hyman, A.L. Pulmonary responses to Nisoldipine. Circulation 64: Supp IV, October 1981, IV, IV-181 (681). 23. Lippton, H.L., Armstead, W., and Kadowitz, P.J. Vasoconstrictor activity of leukotrienes in the feline mesenteric vascular bed. Clinical Research, 30: 1 February 1982. 24. Lippton, H.L., Gruetter, C.A., Ignarro, L.J., Meyer, R.L., and Kadowitz, P.J. Vasosidilator actions of several N-nitroso compounds. Can. J. Physiol. Pharmacol. 60:68-75, 1982. 25. McNamara, D.B., Boineau, F.G., McMullen-Laird, M., Lippton, H.L., She, H.S., Lewy, J.E., and Kadowitz, P.J. Prostaglandin endoperoxide, metabolism by microsomes of whole kidneys from normal, congenital unilateral hydronephrotic and unilateral ureteral obstructed rats. Prostaglandins 24:585-605, 1982.

26. Kadowitz, P.J., Lippton, H.L., McNamara, D.B., Spannhake, E.W., and Hyman, A.L. Action and metabolism of prostaglandins in the pulmonary circulation. Adv Prostaglandin Thromboxane Leukot Res. 1982; 10:333-56.

27. Lippton, H.L., Gottlieb, A.L., Landry, A.Z., and Kadowitz, P.J. Influence of arachidonic acid on vasoconstrictor responses in the rabbit hindquarters vascular bed. Prostaglandins, Leukotrienes and Medicine 12:125-136, 1983.

28. Lippton, H.L., Kadowitz, P.J., and Hyman, A.L. Selective calcium channel blockade by nisoldipine in intact pulmonary vascular bed. Clinical Research, 31:1 February 1983. 29. Lippton, H.L., Armstead, W.M., and Kadowitz, P.J. An analysis of the adrenergic responses and beta- 2 receptor innevation of the feline mesenteric vascular bed. Clinical Research, 31: 1 February 1983. 30. Nandiwada, P.A., Lippton, H.L., Kadowitz, P.J., and Hyman, A.L. Selective Calcium Channel Blockade by Nisoldipine in Intact Pulmonary Vascular Bed. Circulation, 68: Supp III, October 1983, III-35 (139).

12

Howard Lippton

31. Armstead, W.M., Lippton, H.L., and Kadowitz, P.J. An Analysis of the Adrenergic Responses and Beta-2 Receptor Innervation of the Feline Mesenteric Vascular Bed. Circulation, 68: Supp III, October 1983, III-112 (446).

32. Kadowitz, P.J., Lippton, H.L., McNamara, D.B., Wolin, M.S., and Hyman, A.L. Cardiovascular actions of the prostaglandins. In: Cardiovascular Pharmacology. M. Antonaccio (ed.), pp. 453-474, 1984.

33. Lippton, H.L., Armstead, W.M., Hyman, A.L., and Kadowitz, P.J. Vasoconstrictor effects of leukotrienes C4 and D4 in the feline mesenteric vascular bed. Prostaglandins 27:233-243, 1984. 34. Lippton, H.L., Nandiwada, P.A., Hyman, A.L., and Kadowitz, P.J. Influence if cyclooxygenase blockade on responses to isoproterenol, bradykinin and nitroglycerin in the feline pulmonary vascular bed. Prostaglandins 28:253-270, 1984.

35. Lippton, H.L., Horwitz, P.M., McNamara, D.B., Landry, A.Z., and Kadowitz, P.J. Influence of verapamil and dilitiazem on aggregatory responses in cat and rabbit platelet rich plasma. Prostaglandins, Leukotrienes and Medicine 16:121-130, 1984. 36. Lippton, H.L., Hyman, A.L., and Kadowitz, P.J. Pulmonary Vascular Actions of Amrinone and milrinone. Clinical Research, 32:5 February 1984.

37. Hyman, A.L., Lippton, H.L., and Kadowitz, P.J. Selective Enhancement of Pulmonary Vascular Alpha Receptor responses with Elevated Tone. Circulation, 70: Supp II, October 1984, II-33 (130). 38. Harbison, R.G., Lippton, H.L., Hyman, A.L., and Kadowitz, P.J. Pulmonary Vascular Actions of Amrinone and Milrinone. Circulation, 70: Supp II, October 1984, II-182 (726). 39. Philpot, V.B., Lippton, H.L., and Kadowitz, P.J. Effect of aspirin on serum thrombin time and bleeding time. Postaglandins Leukot Med. Aug. 1985; 19(2): 123-30. 40. Kadowitz, P.J., Lippton, H.L., and Hyman, A.L. Influence of a Thromboxane Antagonist on Pulmonary Vasoconstrictor Responses in the Cat. Circulation, 72: Supp III, October 1985, III- 107

(425).

41. Armstead, W.M., Lippton, H.L., Hyman, A.L., and Kadowitz, P.J. Analysis of adrenergic responses in the mesenteric vascular bed of the cat; evidence that vascular beta-2 adrenoceptors are innervated. Can. J. Physiol. Pharmacol. 62:1470-1478, 1985.

42. Hyman, A.L., Lippton, H.L., and Kadowitz, P.J. Autonomic regulation of the pulmonary circulation. J. Cardiovasc. Pharmacol. 7(3): S80-S85, 1985.

43. Lippton, H.L., Horwitz, P.M., McNamara, D.B., Ignarro, L.J., Landry, A.Z., Hyman, A.L., and Kadowitz, P.J. The effects of amrinone on human platelet aggregation: evidence that amrinone does not act through cyclic nucleotide mechanism in platelet rich plasma. Prostaglandins, Leukotrienes and Medicine 18:193-204, 1985.

44. McNamara, D.B., Landry, A.Z., Kerstein, M.D., Hussey, J.L., Ignarro, L.J., Lippton, H.L., Rosenson, R.S., Hyman, A.L., and Kadowitz, P.J. Modulation of coronary arterial prostacyclin synthetase activity. In: International Symposium on Stress and Heart Disease. N.S. Dhalla (ed.), Martinus Nijhoff Publ., Boston pp. 342-352, 1985.

45. McNamara, D.B., Kerstein, M.D., Landry, A.Z., Hussey, J.L., Lippton, H.L., Rosenson, R.S., Hyman, A.L., and Kadowitz, P.J. Coronary arterial prostacyclin synthetase and PGE2 isomerase activities. In: Prostaglandins, Leukotrienes, and Lipoxins. J.M. Baily (ed.), Plenum Publishing Corp., pp. 57-67, 1985.

13

Howard Lippton

46. Hyman, A.L., Lippton, H.L., Ignarro, L.J., Wood, K.S., and Kadowitz, P.J. In: The Pulmonary Circulation and Pulmonary Vascular Injury. S.I. Said (ed.), Futura Publishing Co., Inc., New York pp. 61-99, 1985.

47. Hyman, A.L., Lippton, H.L., Ignarro, L.J., McNamara, D.B., Wood, K.S., and Kadowitz, P.J. Autonomic mechanisms in the pulmonary vascular bed. In: Acute Lung Injury. H. Kazemi (ed.), PSG Publishing Co., Inc., Littleton, MA, pp. 171-200, 1986. 48. Hyman, A.L., Lippton, H.L., and Kadowitz, P.J. Nature of α1 and postjunctional α2 adrenoceptors in the pulmonary vascular bed. Fed. Proc. 45: 2336-2340, 1986. 49. Kadowitz, P.J., Lippton, H.L., McNamara, D.B., Armstead, W.M., and Hyman, A.L. Nisoldipine Inhibits Vasoconstrictor Responses to Methoxamine, BHT 933 and Bay K 8644 in the Feline Pulmonary Vascular Bed. Circulation, 74: Supp II, October 1986, II-239 (957). 50. Underwood, D.C., Lippton, H.L., McNamara, D.B., Hyman, A.L., and Kadowitz, P.J. Analysis of Airway Responses to Platelet Activating (PAF) in the Cat. Circulation, 76: Supp IV, October 1987, IV-234 (930).

51. Lippton,

Contact this candidate